Targeted Cancer Drugs Market Analysed by Espicom in New Topical Report Now Available at MarketPublishers.com

Posted: Published on February 28th, 2012

This post was added by Dr P. Richardson

LONDON--(BUSINESS WIRE)--

The end of 2011 saw the US approval of two new molecularly-targeted cancer drugs, alongside companion diagnostic tests that identify the patients most likely to benefit from treatment. Pfizer's Xalkori (crizotinib) and Roche's Zelboraf (vemurafenib) were both approved following a priority review, highlighting the importance that the FDA has placed on hastening the passage of these therapies to market.

With sales of many blockbuster drugs being cannibalised by generic competitors, pharmaceutical and biotechnology companies are populating their pipelines with candidates directed at novel targets, enhancing development and commercialisation potential. The opportunities for small and medium-sized companies is increasing as the dynamic of the market changes.

New market research study "Targeted Cancer Drugs: The Launch Landscape to 2018" prepared by Espicom examines the current market for targeted cancer drugs, with an overview of both products and players. It covers statistics, competitive rankings, timelines and sector share comparisons. Looking ahead, the report identifies 79 new candidates that are currently under a minimum of Phase II development for solid tumours and provides a timeline detailing estimated launch dates to 2018.

Report Details:

Title: Targeted Cancer Drugs: The Launch Landscape to 2018
Published: February, 2012
Pages: 306
Price: US$ 2,265
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/targeted_cancer_drugs_launch_landscape_to_2018.html

Report Contents:

EXECUTIVE SUMMARY

TARGETED CANCER THERAPIES

What Are Targeted Cancer Therapies?
Why Are New Targeted Cancer Therapies Needed?

APPROVED TARGETED CANCER THERAPIES

Products and Players

WHAT THE FUTURE HOLDS

The Research and Development Pipeline
The Launch Landscape to 2018
Drug Launches By Target
The Players
The Current Players
The New Players
Drug Launches By Indication
Non-small Cell Lung Cancer
Breast Cancer
Colorectal Cancer
Renal Cell Carcinoma
Prostate Cancer
New Indications
Drug Launches By Type
Future Trends

MOLECULAR TARGETS

Established Targets
Novel Targets

TARGETED CANCER THERAPIES UNDER DEVELOPMENT

Vascular Endothelial Growth Factor Inhibitors
Angiocept
Axitinib
BMS-690514
Brivanib
Dovitinib
Linifanib
Motesanib
Ramucirumab
Regorafenib
Telatinib
Tivozanib
Vargatef
Zaltrap
Epidermal Growth Factor Receptor Inhibitors
AZD8931
Dacomitinib
Necitumumab
Neratinib

More new market research reports by Espicom can be found at http://marketpublishers.com/members/espicom/info.html

Here is the original post:
Targeted Cancer Drugs Market Analysed by Espicom in New Topical Report Now Available at MarketPublishers.com

Related Posts
This entry was posted in Drugs. Bookmark the permalink.

Comments are closed.